Dianthus Therapeutics (DNTH) Total Non-Current Liabilities (2018)
Dianthus Therapeutics' (DNTH) quarterly Total Non-Current Liabilities came in at $1.2 million in Q4 2018, up 15.37% quarter-over-quarter from $1.1 million in Q3 2018.
Dianthus Therapeutics (DNTH) Total Non-Current Liabilities (2018) Analysis & Trends
Dianthus Therapeutics' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $1.2 million for Q4 2018.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $1.2 million in Q4 2018; TTM through Dec 2018 was $1.2 million, a N/A change from a year earlier, with the FY2018 full-year figure at $1.2 million, changed N/A from the prior year.
- Total Non-Current Liabilities grew to $1.2 million in Q4 2018 per DNTH's latest filing, from $1.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.2 million in Q4 2018 and bottomed at $796000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Dianthus Therapeutics | 3.92 Bn | 3.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.25 Mn |
| Sep 30, 2018 | 1.08 Mn |
| Jun 30, 2018 | 796,000.00 |